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Introduction
The membrane attack complex inhibitory protein
CD59 and Decay Accelerating Factor CD55 are two of
the key members of the family of complement regula-
tory proteins (CRPs), molecules protecting autologus
cells against inappropriate complement activation
[10]. Protection effect is achieved by interfering with
the assembly of the membrane attack complex and the
insertion of complement 9 into the cell membrane
[33], thus preventing formation of membrane attack
complexes (MAC). CD59 binds to preformed C5b-8
complex in a way that blocks polymerisation of C9
molecules forming the channel of MAC. Additionally
to complement regulatory function, CD59 acts as a
signal transduction molecule [11]. The primary role of
CD55 is deactivation of complement (C3and C5) con-
vertases [31]. Both CD59 and CD55 proteins are
attached to the external surface of the cell membrane
by glycosylphosphatidylinositol (GPI) moiety attached
to their C-terminal end enabling high mobility of the
molecule within the biological membranes. The mole-
cules acting on two different levels of complement
activation are very effective elements of anti-comple-
ment shield. The ability of CD59 and CD55 to stop the
complement-mediated damage has been used to devel-
op strategies aimed at creation of transgenic animals
which serve as organ donors for clinical applications
[1, 7-9, 12, 18, 26, 27, 29, 35]. The observed protective
effect preventing rejection of xenotransplants raises
the question about possible involvement of CRPs in
the selection of lymphocytes in human thymus.
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Abstract: CD59 is one of the key molecules involved in cell protection against autologus complement. The fact that com-
plement regulatory proteins are able to prevent hyperacute rejection of organs in pig to primate model, raises the question
of possible complement regulatory protein (CRP) involvement in the maturation of immunological system. We report here
that in foetal and postnatal human thymus, CD59 and CD55 are primarily located on Hassall's corpuscles and medullary
epithelial cells. This localization highly correlates with the expression of CD30L, which is the member of the tumour necro-
sis factor superfamily. Additionally, TUNEL technique was used to visualize distribution of apoptotic cells in the thymus,
which revealed the presence of apoptotic cells closely associated with the Hassall's corpuscles. The observed co-localiza-
tion of CD59, CD55 and CD30L might suggest an involvement of the complement system in thymic selection in humans. 
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Uncontrolled overexpression of CD59 and CD55 on
thymocytes might result in decreased sensitivity of these
cells to complement-mediated damage and in turn pro-
tect them from immunologic surveillance, as demon-
strated in case of several malignant tumour cells [16, 30,
48]. As leukaemic blasts are protected by relatively high
expression of CRPs [17], the precise regulation of GPI-
anchored CRPs distribution in thymus seems very
essential for the normal function of this organ. Numer-
ous investigators have extensively studied the distribu-
tion of CD59 proteins in the human organism [2, 20-23,
28, 32, 36, 37, 42, 47] but there is almost no information
available about its morphological localisation in thy-
mus. The aim of the present study was to elucidate the
distribution of CD59 in human thymus. 
Materials and methods
Materials and reagents. The study was performed on 9 thymus
samples obtained from humans of different age. Thymuses were
obtained as surgical waste material removed during corrective
heart surgery. Three of them were foetal (age 6-8 months of preg-
nancy) obtained during autopsy. The other six thymuses were
obtained during surgery (age 0-13 years of age).  CRPs were local-
ized in standard paraffin sections using immunohistochemical
methods. Indirect biotin-avidin-peroxidase technique with two dif-
ferent anti-human CD59 monoclonal antibodies: rat IgG clone
YTH.53.1 (Serotec® Kidlington, UK) and mouse IgG Clone
MEM-43 (Cymbus, Hampshire, UK). CD55 was identified with
mouse monoclonal antibodies (Serotec® Kidlington, UK). CD30L
antibody was purchased from Genzyme Diagnostics® (Cambridge,
MA).  Macrophages were localised using monoclonal antibody
NCL-LN5 (Novocastra® Newcastle upon Tyne, UK). Thymocytes
were identified by staining with mouse anti CD3 monoclonal anti-
bodies (Novocastra® Newcastle upon Tyne, UK). Apoptotic cells
were localised using TUNEL technique (ApopTag™ Oncor®,
Gaithersburg, MD).
Immunohistochemistry. The thymic tissue was fixed in standard
4% paraformaldehyde aqueous solution and embedded in paraffin.
Staining was performed on 8 µm paraffin sections which were first
heated at 56°C for 60 min and then deparaffinised. Additionally,
high temperature unmasking technique was used. In brief, slides
were boiled in 0.01 M sodium citrate buffer (2.94 g/l of tri-sodium
citrate solution adjusted to pH 6.0 using 1.0 M HCl) in a pressure
cooker for about 5 min. After the heat treatment, slides were
washed in TBS (Tris buffered saline). After quenching endogenous
peroxidase with 0.5% H2O2 in methanol for 30 min, sections were
blocked with horse serum for 30 min at room temperature and
exposed to monoclonal antibodies at 4°C overnight. Staining was
performed using anti-CD59 monoclonal antibodies (rat YTH 53.1
and mouse MEM43) (1:100) anti-CD3 antibodies, NCL-LN5 anti-
bodies (1:50) and anti-CD30L antibody (1:50). Visualisation of
antibodies was obtained using ABC technique according to manu-
facturer's protocol (Novocastra ABC kit, cat. no. NCL-ABCu).
DAB (Sigma®)  was used as chromogen. Sections were counter-
stained with haematoxylin and mounted in glycerol-gelatin
(Sigma®). Isotypic antibodies (Serotec® Kidlington, UK) were
used as a control. 
TUNEL method. Detection of apoptotic cells was performed
using commercial kit (ApopTag™ (Oncor®, Gaithersburg, MD),
according to manufacturers recommendations.  Briefly, after
deparaffinization slides were incubated in 1 µg/ml of  Proteinase K
in 10 mM Tris solution for 15 min at room temperature. Endoge-
nous peroxidase activity was blocked by incubation in 3% hydro-
gen peroxide in phosphate buffered saline (PBS). The sections
were then  incubated with terminal deoxynucleotidyl transferase at
37°C for 60 min (adding the digoxigenin-conjugated dUTP to the
3'-OH ends of fragmented DNA). To detect the digoxigenin-
labelled nucleotides, specific antibodies conjugated with peroxi-
dase were used. The sections were stained with 4-chloro-1-naphtol
(CN). Apoptotic cells were stained dark blue.
Results
In foetal thymus (3 cases examined), CD59 was iden-
tified predominantly on Hassall's corpuscles (Fig. 1) in
the medulla, decreasing its expression during the first
year after birth (3 cases). In thymuses obtained from
older patients (more than 1 year old, 3 cases), CD59
was still detectable on Hassall's corpuscles (Fig. 3A)
but only when high temperature unmasking technique
was used. The distinctive feature of the staining was
the multilayered pattern of Hassall's corpuscles (Fig.
2). The staining pattern was similar for anti-CD59
(YTH.53.1 and MEM 43) and anti-CD55 monoclonal
antibodies used in the study (Fig. 3B). The results of
TUNEL staining revealed accumulation of apoptotic
cells in close contact with the Hassall's corpuscles
(Fig. 3C). Apoptotic cells were also distributed "ran-
domly" in other parts of thymus (not shown). Staining
with anti-CD30L antibody revealed distribution of this
protein mainly on Hassall's corpuscles, which was
similar to that of CD59 and CD55 (Fig. 3D). A differ-
ent pattern of staining was observed when the sections
where labelled with monoclonal anti-CD3 antibodies
(Fig. 3E) or macrophage marker (LN5 MoA) (Fig. 3F).
In both cases Hassall's corpuscles were negative, while
positive cells (CD3 and LN5) were present in large
numbers in thymic medulla and cortex. Isotypic con-
trols revealed no unspecific binding of antibodies to
Hassall's corpuscles. Additionally it was observed that
CD3-positive thymocytes and LN5-positive phagocyt-
ic cells had low level of CD59 and CD55 expression.
The level of CD59 and CD55 expression on thymo-
cytes increased with age and was dependent on the
region of thymus. It was not detectable in cortex and
increased toward the medullary region.
Discussion
Despite the widespread interest in thymus develop-
ment [4-6, 39], relatively little is known about the role
and origin of Hassall's corpuscles. These structures
consisting of several layers of cell membranes are fre-
quently found in the thymic medulla of thymus. The
number of Hassall's corpuscles increases with age,
indicating their involvement in thymus maturation.
Additionally, the morphology of Hassall's corpuscles
changes with age: in foetal thymuses they are relative-
ly small and regularly shaped in contrast with struc-
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tures appearing during first years of life [38]. The pat-
tern of CD59 staining in thymus was almost identical
to that observed by other authors in case of CD30L
[41]. This observation and the localization of apoptot-
ic cells in close contact with CD59-positive cells,
might suggest that those two molecules might play an
important role in thymic selection in man. This
hypothesis is also supported by clusterin distribution
in rat thymus [13, 14]. Clusterin, which is analogous in
function to CD59 in preventing MAC formation [45],
is highly expressed  in the medullary region of thymus
[13, 14]. This localisation together with low level of
CD59 on thymocytes indicates possible high suscepti-
bility of immature thymocytes to complement attack.
It is possible that CD59 expression increases on Has-
sall's corpuscles because of close association with
apoptotic thymocytes in a similar way as proposed in
case of clusterin [25, 40].
It might be also hypothesized that Hassall's corpus-
cles act as CD59 scavengers, collecting CRPs from
apoptotic thymocytes. As outer layers of cells forming
Hassall's corpuscles are closely associated with apop-
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Fig. 1. CD59 distribution in foetal human thymus.  Arrows are pointing to Hassall's corpuscles. × 100. Fig. 2. CD59 localization within
Hassall's corpuscles from foetal human thymus. Clearly visible association of CD59 with membranes (arrow). × 600. Fig. 3. A. CD59
localisation in human postnatal thymus on Hassall's corpuscle and nursing cells (arrow). × 200. B. CD55 localisation on foetal Hassall's
corpuscle. × 200. C. Apoptotic cells (indicated by arrow) in close association with outer layer of Hassal corpuscle. Postnatal thymus
(TUNEL method). × 200. D. CD 30L immunostaining of Hassall's corpuscle. × 400. E.  Thymocytes surrounding Hassall's corpuscle.
CD3 immunostaining. × 400. F.  Postnatal thymus stained with macrophage marker, antibody NL-5. × 200.
totic cells, it might be hypothesised that they act in a
similar way as high endothelial venule cells [19].
The signal from CD30L transduced into cells via
TNF receptors seems to induce not only apoptosis in
negatively selected thymocytes, but also CD59
release from the cell surface, rendering thymocytes
vulnerable to complement attack. Transfer of CRPs
can be facilitated by the close physical association
between thymocytes and stromal cells [43]. Decrease
in CRP expression has been already observed during
apoptosis of peripheral granulocytes [24] and lym-
phocytes [3, 23, 46]. On the other hand, increased
expression of CRPs on lymphomas has been identi-
fied as an element of evading  immunological sur-
veillance [15, 34, 44]. It might be hypothesised that
CD59-deficient thymocytes even when released from
thymus might be eliminated from the organism by
simple complement activation. iC3b-coated apoptotic
vesicles might be phagocytosed by spleen and/or
liver macrophages. This mechanism might explain
the apparent inconsistency between death rate in thy-
mus and the capacity of thymic macrophages to
destroy cell debris. The observed increased surface
expression of CRPs on medullary thymocytes might
suggest that maturation of thymocytes might be asso-
ciated with the acquisition of resistance to comple-
ment attack. 
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